赛隆药业(002898) - 2025 Q3 - 季度财报

Revenue and Profitability - The company's revenue for Q3 2025 was ¥64,314,137.14, representing a 2.60% increase year-over-year, while the year-to-date revenue decreased by 8.56% to ¥200,021,471.55[5] - The net profit attributable to shareholders for Q3 2025 was -¥25,565,959.76, a significant decline of 368.44% compared to the same period last year, with a year-to-date net profit of -¥40,398,114.67, down 993.92%[5] - The basic and diluted earnings per share for Q3 2025 were both -¥0.1452, reflecting a decrease of 368.39% year-over-year, with year-to-date earnings per share at -¥0.2295, down 992.86%[5] - The net loss attributable to the parent company was CNY -23,661,161.79, compared to a profit of CNY 16,736,952.88 in the previous period[17] - Operating profit was recorded at -¥38,388,804.68, a substantial decrease from -¥3,320,491.30 in the prior period[21] - The basic and diluted earnings per share were both reported at -¥0.2295, compared to -¥0.0210 in the previous period, reflecting a deterioration in earnings performance[21] Operating Costs and Expenses - Operating costs increased by 31.36% to ¥156,794,132.55 due to the addition of AI server business in the current period[10] - Total operating costs increased to CNY 230,411,567.02, up 4.0% from CNY 220,696,045.74 year-over-year[19] - Research and development expenses were ¥14,287,394.58, down from ¥18,620,749.38, indicating a reduction in investment in innovation[21] - The company incurred financial expenses of ¥5,395,984.49, an increase from ¥4,957,412.44, primarily due to higher interest expenses[21] Cash Flow and Investments - The company's cash flow from operating activities showed a year-to-date net outflow of -¥36,788,916.03, a decrease of 15.93% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of -¥36,788,916.03, worsening from -¥31,732,542.11 in the previous period[23] - Investment activities resulted in a net cash outflow of -¥14,084,522.42, compared to -¥11,796,796.53 in the prior period, indicating increased investment expenditures[23] - The company raised ¥164,900,000.00 through financing activities, an increase from ¥98,250,720.00 in the previous period, showing improved access to capital[23] Assets and Liabilities - The total assets at the end of Q3 2025 were ¥797,544,165.12, a decrease of 1.32% from the end of the previous year[5] - Total current assets amounted to CNY 253,147,648.77, slightly up from CNY 249,830,978.43 at the start of the quarter[16] - Total liabilities increased to CNY 337,069,742.75 from CNY 308,946,095.60, reflecting a rise of 9.1%[17] - The company's total assets decreased to CNY 797,544,165.12 from CNY 808,223,377.29, a decline of 1.0%[17] - Cash and cash equivalents decreased to CNY 27,830,758.51 from CNY 48,843,383.16, a decline of 43.1%[15] - Short-term borrowings decreased to CNY 104,949,797.22 from CNY 128,134,459.63, a reduction of 18.1%[16] Prepayments and Contract Liabilities - The company reported a significant increase in prepayments, rising by 1173.97% to ¥38,526,698.80, primarily due to increased procurement prepayments[8] - The company reported a significant increase in prepayments, which rose to CNY 38,526,698.80 from CNY 3,024,135.40, indicating a growth of 1,272.5%[15] - The company experienced a 200.95% increase in contract liabilities, reaching ¥34,630,933.57, attributed to an increase in advance payments received[8] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,265, with the largest shareholder holding 38.36% of the shares[12] Inventory and Credit Impairment - Inventory at the end of the quarter was CNY 99,598,057.39, an increase of 5.3% from CNY 94,077,645.27 at the beginning of the period[16] - The company recorded a 68.00% reduction in credit impairment losses, amounting to -¥843,432.47, due to a decrease in accounts receivable[10]